Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1929134 | 0.79 | LTA4H (0.52) | LTA4HPTGS2PSMB1PSMB5PSMB2 | |
| SCHEMBL1929030 | 0.79 | LTA4H (0.50) | LTA4HPTGS2PSMB1PSMB5PSMB2 | |
| SCHEMBL1927451 | 0.76 | ESR1 (0.56) | SMN1; SMN2TSHRL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1927551 | 0.75 | KCNH2 (0.51) | LTA4HPTGS2SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL1928729 | 0.75 | KCNH2 (0.51) | LTA4HPTGS2SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL9998836 | 0.73 | HRH3 (0.46) | SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL27540906 | 0.72 | CACNA1F (0.44) | SMN1; SMN2HRH3TSHRKDM4EALDH1A1 | |
| SCHEMBL1928309 | 0.72 | ENPP1 (0.53) | SMN1; SMN2HRH3KCNH2L3MBTL1KDM4E | |
| SCHEMBL2321726 | 0.70 | KDM4E (0.69) | TSHRKDM4EALDH1A1KMT2A | |
| SCHEMBL1776035 | 0.70 | HRH3 (0.62) | HRH3KCNH2ATML3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | LTA4H 1678/4885PTGS2 1709/4885PSMB1 4153/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | LTA4H 2569/4885PTGS2 1769/4885PSMB1 3954/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | LTA4H 1678/4885PTGS2 1709/4885PSMB1 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.